Navigation Links
SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
Date:3/11/2009

patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's ability to fund our operations until late 2009, the success of its products in the marketplace and in clinical trials and potential partnership opportunities for its product candidates. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including unanticipated costs and expenses associated with our product development, clinical activities and regulatory review, reductions in our royalty revenues, our ability to successfully develop new formulations and complete research and development, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. For example, if we are not successful in raising additional capital or securing partnership arrangements, we may not be able to advance development and commercialize our products. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
7. China Biopharma, Inc. Announces New Plan of Operation
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
10. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 US demand to rise 3.9% annually ... is forecast to rise 3.9 percent per year to ... projected to increase 1.3 percent per year to 1.5 ... in construction expenditures will support demand for biocides in ... growth in consumer spending and manufacturing output will support ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
(Date:9/21/2014)... first time, scientists have discovered how to produce ultra-thin ... stiffness greater than that of today,s strongest nanotubes and ... team led by John V. Badding, a professor of ... the 21 September 2014 issue of the journal ... view, our discovery is intriguing because the threads we ...
Breaking Biology Technology:US Biocides Market 2US Biocides Market 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4
... - From less than 1 million to 600 ... growth in the past 10 years. , ,From the ... job, providing better tools for finding, filtering and presenting ... decade on the Web and also looking forward to ...
... Madison, Wis. - Stratatech Corporation , a UW ... from the National Institute on Aging, for the development of ... wounds such as diabetic, venous stasis and pressure ulcers, which ... estimated that in the United States alone, millions of people ...
... Madison, Wis. Pierce Biotechnology , a ... BioSurfaces of Madison, Wis., to distribute GenTel's trademarked ... use of GenTel technology in developing new protein arrays ... specifically designed for protein-array applications, including the profiling of ...
Cached Biology Technology:Internet Scout celebrates 10 years on web, eyes new project launch 2
(Date:9/22/2014)... New Haven, Conn. Yale University researchers are studying ... pulmonary fibrosis, a respiratory disease in which scars develop ... treatment uses a microRNA mimic, miR-29, which is delivered ... only blocked pulmonary fibrosis, it reversed fibrosis after ... in the journal EMBO Molecular Medicine . , ...
(Date:9/22/2014)... molecular cog in a plant,s biological clock one ... on temperature. , Transcription factors, or genetic switches, drive ... such as light, rain, soil quality, or even animals ... has isolated one, called FBH1, that reacts to temperature ... while in keeping it on a consistent track. , ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Genetic switch regulates a plant's internal clock based on temperature 2
... Recognizes Leadership in Technology and Innovation in Global ... LMT ) has been named the ... Frost and Sullivan, recognizing the Corporation,s leadership in ... of customers. Frost and Sullivan based the award ...
... The Centre for Genomic Regulation (CRG) in Barcelona, Spain ... by Genomatix Software GmbH. , GGA comprises purpose built ... software providing a complete solution for the analysis of ... genome. "In regards to the machine, I love ...
... 4, 2009 The incidence of pneumothorax (PTX), or collapsed ... has been reported to range from 13 50 percent, ... In people, PTX is reported to be the most preventable ... ultrasound has been infrequently used as a non-invasive, point-of-care imaging ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CRG buys Genomatix' Next Generation Sequencing analysis solution 2Novel veterinary procedure detecting life-threatening injuries touted 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: